Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Scottsdale, Arizona 85258


To evaluate the safety and efficacy of cefdinir oral suspension in children between 6 months and 4 years of age, with acute otitis media, who are at risk of persistent or recurrent otitis media.


Inclusion Criteria: - Male and female children between 6 months and 4 years of age - Weight does not exceed 40 kg - Clinical diagnosis is acute otitis media - Have evidence of middle ear fluid - At risk for persistent or recurrent otitis media - Generally in good health Exclusion Criteria: - Sensitivity or allergy to penicillins or cephalosporins or inability to take oral medications - Presence of tympanostomy tubes, ventilation tube or perforated tympanic membrane, in either ear - Treatment with any anti-infective agent within 3 days prior to the study or treatment with a long-acting injectable antimicrobial agent (e.g. , penicillin G benzathine) within 4 weeks prior to the study - Concomitant infection, that requires additional antimicrobial therapy - Presence of a disease, complicating factor (e.g., mastoiditis), or structural abnormality that would preclude evaluation of the patient's therapeutic response

Study is Available At:

Original ID:




Secondary ID:

Study Acronym:

Brief Title:

Safety and Efficacy Study of Cefdinir Oral Suspension, in Pediatric Subjects to Treat Acute Otitis Media

Official Title:

An Open-Label, Safety and Efficacy Study of Cefdinir Oral Suspension, 25 mg/kg Once Daily, in Pediatric Subjects With Acute Otitis Media

Overall Status:


Study Phase:

Phase 2/Phase 3



Minimum Age:

6 Months

Maximum Age:

4 Years

Quick Facts

Healthy Volunteers
Oversight Has DMC
Study Is FDA Regulated
Study Is Section 801
Has Expanded Access

Study Source:


Oversight Authority:

United States: Food and Drug Administration

Reasons Why Stopped:

Study Type:


Study Design:

Allocation: Non-Randomized, Intervention Model:

Number of Arms:


Number of Groups:


Total Enrollment:


Enrollment Type:


Study Dates

Start Date:July 2002
Primary Completion Date:April 2003
Primary Completion Type:Actual
Verification Date:March 2008
Last Changed Date:March 20, 2008
First Received Date:March 20, 2008

Study Outcomes

Outcome Type:Secondary Outcome
Measure:Laboratory evaluations
Time Frame:30 days
Safety Issues:True
Outcome Type:Secondary Outcome
Measure:Adverse events assessment
Time Frame:45 days with follow-up to a satisfactory conclusion
Safety Issues:True
Outcome Type:Secondary Outcome
Measure:Physical exam; Vital signs; Use of concomitant medications
Time Frame:59 days
Safety Issues:True
Outcome Type:Primary Outcome
Measure:Change in the otoscopic findings
Time Frame:30 days
Safety Issues:False
Outcome Type:Primary Outcome
Measure:Clinical response
Time Frame:30 days
Safety Issues:False
Outcome Type:Primary Outcome
Measure:Bacteriological Response
Time Frame:30 days
Safety Issues:False

Study Interventions

Intervention Type:Drug
Description:cefdinir oral suspension, 25 mg/kg once daily for 10 days
Arm Name:1
Other Name:ABT-198, Omnicef, cefdinir

Study Arms

Study Arm Type:Other
Arm Name:1

Study Agencies

Agency Class:Industry
Agency Type:Lead Sponsor
Agency Name:Abbott

Sample and Retention Information

There are no available Sample and Retention Information

Study References

There are no available Study References

Data Source: ClinicalTrials.gov

Date Processed: November 18, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

This study is not currently recruiting Study Participants. The form below is not enabled.